Tag Archives: Hepatitis C Virus

September, 2018

October, 2017

December, 2016

  • 14 December

    Let’s Screen Everyone

    Too many people infected with the hepatitis C virus (HCV) simply don’t know their disease status. As many as one in four cases of HCV infection are undiagnosed, as I pointed out in a blog earlier this year (Finding the Missing Cases), even when current federal guidelines for hepatitis C …

November, 2016

  • 22 November

    HCV Research Round-up

    Hepatitis C treatment options continue to be a vibrant field full of exciting research, including the following: Genotype 3 of the hepatitis C virus (HCV) has remained harder-to-treat among the six main genotypes. New research presented at the 2016 AASLD conference now offers promising news for treating genotype 3. According …

August, 2016

  • 5 August

    Major Treatment Expansion Could Essentially Eliminate Hepatitis C in R.I. by 2030

    PROVIDENCE, R.I. [Brown University] — A new Brown University study projects that increasing the number of Rhode Islanders treated every year for hepatitis C virus infection (HCV) to about 2,000 by 2020 would reduce cases by 90 percent and prevent more than 70 percent of expected liver-related deaths in the …

  • 3 August

    HCV Blues

    By some estimates, depression is experienced by up to one in every three people with chronic hepatitis C virus (HCV) infection. This is accounted for, in part, by the risk of depression that occurs in chronic, long-term diseases of all kinds. For hepatitis C specifically, depression remains a common yet …

July, 2016

  • 27 July

    Discovery of New Hepatitis C Virus Mechanism

    Researchers at Osaka University, Japan uncovered the mechanisms that suppress the propagation of the hepatitis C virus (HCV) with the potential of improving pathological liver conditions. Using model mice, they confirmed that when a certain enzyme is inhibited, HCV particle production is reduced leading to an improvement of pathological liver …

January, 2016

  • 5 January

    FDA Grants Priority Review to Gilead’s Latest Hepatitis C Combo

    FOSTER CITY, Calif.–(BUSINESS WIRE)–Jan. 4, 2016– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the company’s New Drug Application (NDA) for an investigational, once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi® in …